Journal ArticleDOI
Anti-cancer drugs
Reads0
Chats0
About:
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.read more
Citations
More filters
Journal ArticleDOI
The status of platinum anticancer drugs in the clinic and in clinical trials.
TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI
Natural products to drugs: natural product derived compounds in clinical trials
Mark S. Butler,Mark S. Butler +1 more
TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Cellular distribution and functions of P2 receptor subtypes in different systems.
TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI
Natural products: an evolving role in future drug discovery.
Bhuwan B. Mishra,Vinod K. Tiwari +1 more
TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.
References
More filters
Journal ArticleDOI
Discorhabdins and pyrroloiminoquinone-related alkaloids.
TL;DR: Discorhabdins and Pyrroloiminoquinone-Related Alkaloids and their applications in Brain Functional Genomics and Drug Discovery are proposed.
Journal ArticleDOI
Chemical diversity of propolis makes it a valuable source of new biologically active compounds
Journal ArticleDOI
DNA minor groove binders: back in the groove.
TL;DR: A look at how minor groove binding agents have progressed from the lab through the clinic with particular emphasis on identifying the contexts of vulnerabilities of patient tumors which increase the effectiveness of these drugs.
Journal ArticleDOI
Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma
Sujatha Venataraman,Irina Alimova,Peter Harris,Diane K. Birks,Illango Balakrishnan,Marc Remke,Michael D. Taylor,Michael H. Handler,Nicholas K. Foreman,Rajeev Vibhakar +9 more
TL;DR: It is reported that MYC driven medulloblastoma can be targeted by inhibition of the bromodomain protein BRD4 and the feasibility of BET domain inhibition as a therapeutic approach in vivo is demonstrated.
Journal ArticleDOI
Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)
TL;DR: Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells, but one patient developed fatal pneumocystis carinii pneumonia.